Arthur Kirsch, M.B.A.

Arthur Kirsch joined Evommune’s board of directors in October 2025. Mr. Kirsch currently serves as a board member, chairman of Audit Committee, and a member of the Compensation Committee at Liquidia Corporation (Nasdaq: LQDA). Mr. Kirsch is also a director and member of the Audit and Compensation Committees at Atea Pharmaceuticals (Nasdaq: AVIR). Mr. Kirsch previously served as a director of multiple public companies, including, POZEN (Nasdaq: POZN), Aralez Pharmaceuticals (Nasdaq: ARLZ), Kadmon Corporation (NYSE: KDMN) and Immunomedics (Nasdaq: IMMU). Mr. Kirsch is a senior advisor at Alvarez & Marsal and a managing director and senior advisor for GCA Global, a global investment banking firm. Previously in his career, Mr. Kirsch was executive vice president, head of research at Vector Securities, a brokerage firm as well as president of Natwest Securities Limited, a brokerage firm. Mr. Kirsch worked at Drexel Burnham Lambert, an investment banking firm, where he held the position of executive vice president, head of equity division. Mr. Kirsch graduated from the University of Rhode Island with a Bachelor of Science and holds a Master of Business Administration from Baruch College.